Breaking News
Get 55% Off 0
Get Premium Data for Cyber Monday: Up to 55% Off InvestingPro
CLAIM SALE
Close

Cardiff Oncology Inc (CRDF)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Cardiff Oncology's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
2.310 -0.030    -1.28%
06/12 - Closed. Currency in USD
After Hours
2.310
0.000
0.000%
19:29:36 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 669,738
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 2.260 - 2.485
Cardiff Oncology 2.310 -0.030 -1.28%

Cardiff Oncology Inc Company Profile

 
Get an in-depth profile of Cardiff Oncology Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

-

Equity Type

ORD

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Contact Information

Address 11055 Flintkote Avenue
San Diego, 92121
United States
Phone 858 952 7570
Fax -

Top Executives

Name Age Since Title
Sandra L. Silberman 65 2017 Member of Clinical Advisory Board
Filip Janku 47 - Member of Clinical Advisory Board
Emmanuel Antonarakis - 2020 Member of Clinical Advisory Board
Mark Erlander 61 2013 CEO & Director
Rodney S. Markin 64 2014 Independent Chairman of the Board
Gary W. Pace 73 2020 Independent Director
Renee P. Tannenbaum 70 2021 Independent Director
Lale White 66 2020 Independent Director
Carlo Maria Croce - - Member of Scientific Advisory Board
Paul R. Billings 70 2012 Member of Scientific Advisory Board
Charles R. Cantor 79 - Member of Scientific Advisory Board
Michael B. Yaffe - 2018 Member of Clinical Advisory Board
Glenn J. Bubley - 2018 Member of Clinical Advisory Board
Heinz-Josef Lenz 62 2020 Member of Clinical Advisory Board
Alberto Bardelli - 2014 Member of Scientific Advisory Board
Brunangelo Falini - 2010 Member of Scientific Advisory Board
K. Peter Hirth 70 2014 Member of Scientific Advisory Board
James O. Armitage 75 2020 Independent Director
Mani Mohindru 50 2021 Independent Director
Amer Zeidan - 2020 Member of Clinical Advisory Board
Riccardo Dalla-Favera 70 2010 Member of Scientific Advisory Board
David Einstein - 2018 Member of Clinical Advisory Board
Adam Schayowitz - - Member of Scientific Advisory Board
Christoph Reinhard - - Member of Scientific Advisory Board
Nicholas Choong - 2024 Member of the Scientific Advisory Board
Josep Tabernero Caturla - - Member of Scientific Advisory Board
Eric Van Cutsem - - Member of Scientific Advisory Board
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

CRDF Comments

Write your thoughts about Cardiff Oncology Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Ace Geo
Ace Geo Mar 01, 2024 1:17PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Regardless of how this operates in the short term, it's still very undervalued.
MIKHAIL KUZNETSOV
MIKHAIL KUZNETSOV Jan 30, 2022 7:09AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I really like this failure, I bought it for $ 3, I hope it will fly into the stratosphere soon!!!
criptomonedas ripple cardano
criptomonedas ripple cardano Dec 03, 2021 1:36AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
cardiff 100$
Joe Montana
Joe Montana Apr 26, 2021 10:05PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
about to pop
Shahan Khan
Shahan Khan Mar 08, 2021 7:50AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
11.20 soon
Dee Trinbagonian
Dee Trinbagonian Feb 27, 2021 3:25PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
To the moon 🚀
Jobir Avezov
Jobir Avezov Feb 02, 2021 1:12PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Wow its going to gain sooner
Aktieris Vanjaa
Aktieris Vanjaa Jan 24, 2021 12:22PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Zman Any tips for bull?
Zman Trading
ZmanTrading Jan 24, 2021 12:22PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Setting SL $10.18 and still my short term target is $14.
Zman Trading
ZmanTrading Jan 24, 2021 12:22PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Zman Trading Don’t look right. Sold with loss at $10,34. Good luck to those who still hang on!
Jobir Avezov
Jobir Avezov Jan 24, 2021 12:22PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Zman Trading No hopes mate
Aaron Strong
Aaron Strong Jan 24, 2021 12:22PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Zman Trading good call👎
Ahmad AL-s
Ahmad AL-s Jan 24, 2021 12:22PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Zman Trading  i think its a good buy now
Zman Trading
ZmanTrading Jan 24, 2021 11:05AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
https://seekingalpha.com/article/4400581-first-look-cardiff-oncology
Zman Trading
ZmanTrading Jan 21, 2021 4:17PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
In green! Very important step in the right direction. Price is at +11.45% from yesterdays low!
Zman Trading
ZmanTrading Jan 21, 2021 4:17PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Higher high and higher low on the daily!
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email